These relatively less-aggressive tumor characteristics of HER2-low breast cancer may be the reason why HER2-low breast cancer has favorable prognosis even though the response to systemic treatment is not different compared to HER2-0 breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.